Cramer’s Home Work: A New Biopharma Idea

Friday, 3 May 2013 | 6:46 PM ET
You Ask, Cramer Answers! Buy Trius?
Friday, 3 May 2013 | 6:45 PM ET
Mad Money viewers ask Jim Cramer investment questions. While Trius Therapeutics is highly speculative and not for the faint of heart, I do like the risk reward here, explains Cramer.

(Having trouble with the video? Click here!)

Sometimes Jim Cramer tells a caller that he needs to do homework before he can make a decision on a stock. And he's not kidding.

Following is Cramer's research or homework on a stock recently called to his attention by an investor who watches the TV show.

Tooga | Getty Images

Trius Therapeutics

On Wednesday May 1, Jeff in California asked about Trius Therapeutics a biopharma company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.

As with so many companies in this sector, Cramer believes the fortunes of Trius are tied to the success of its pipeline. And Cramer's homework suggests that the pipeline shows promise.

Read More from Mad Money with Jim Cramer
Cramer: Shifting Winds Sweeping Street
Energy Quest: Cramer's Gulf Plays
Allergan's Latest FDA Victory

"I think their drug Tedizolid, for MRSA skin infections, has a solid chance for approval in the back half of the year," Cramer said. "The company has $100 million in cash to fund commercial operations, and Tedizolid could garner peak sales of $800 million. So I favor the risk reward here, but please use price limits. Biotech investing is tricky, especially within these tiny micro caps."

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

  Price   Change %Change


Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.